These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32611374)

  • 41. Plasma miR-200b in ovarian carcinoma patients: distinct pattern of pre/post-treatment variation compared to CA-125 and potential for prediction of progression-free survival.
    Kapetanakis NI; Uzan C; Jimenez-Pailhes AS; Gouy S; Bentivegna E; Morice P; Caron O; Gourzones-Dmitriev C; Le Teuff G; Busson P
    Oncotarget; 2015 Nov; 6(34):36815-24. PubMed ID: 26416421
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum microRNA-92 expression in patients with ovarian epithelial carcinoma.
    Guo F; Tian J; Lin Y; Jin Y; Wang L; Cui M
    J Int Med Res; 2013 Oct; 41(5):1456-61. PubMed ID: 23963852
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum microRNA-145 as a novel biomarker in human ovarian cancer.
    Liang H; Jiang Z; Xie G; Lu Y
    Tumour Biol; 2015 Jul; 36(7):5305-13. PubMed ID: 25722112
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MicroRNA-200c as a Prognostic Biomarker for Pancreatic Cancer.
    Paik WH; Song BJ; Kim HW; Kim HR; Hwang JH
    Korean J Gastroenterol; 2015 Oct; 66(4):215-20. PubMed ID: 26493507
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes.
    Shapira I; Oswald M; Lovecchio J; Khalili H; Menzin A; Whyte J; Dos Santos L; Liang S; Bhuiya T; Keogh M; Mason C; Sultan K; Budman D; Gregersen PK; Lee AT
    Br J Cancer; 2014 Feb; 110(4):976-83. PubMed ID: 24366298
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Independent Validation of a Diagnostic Noninvasive 3-MicroRNA Ratio Model (
    Fredsøe J; Rasmussen AKI; Laursen EB; Cai Y; Howard KA; Pedersen BG; Borre M; Mouritzen P; Ørntoft T; Sørensen KD
    Clin Chem; 2019 Apr; 65(4):540-548. PubMed ID: 30728149
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
    Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
    Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
    PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics.
    Koutsaki M; Spandidos DA; Zaravinos A
    Cancer Lett; 2014 Sep; 351(2):173-81. PubMed ID: 24952258
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Value of Plasma-Based MicroRNAs as Diagnostic Biomarkers for Ovarian Cancer.
    Wang W; Yin Y; Shan X; Zhou X; Liu P; Cao Q; Zhu D; Zhang J; Zhu W
    Am J Med Sci; 2019 Oct; 358(4):256-267. PubMed ID: 31353030
    [TBL] [Abstract][Full Text] [Related]  

  • 51. miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma.
    Arts FA; Keogh L; Smyth P; O'Toole S; Ta R; Gleeson N; O'Leary JJ; Flavin R; Sheils O
    Hum Pathol; 2017 Dec; 70():98-104. PubMed ID: 29079174
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of urinary cell-free miR-210 as a potential tool of liquid biopsy for clear cell renal cell carcinoma.
    Li G; Zhao A; Péoch M; Cottier M; Mottet N
    Urol Oncol; 2017 May; 35(5):294-299. PubMed ID: 28089386
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells.
    Yoshimura A; Sawada K; Nakamura K; Kinose Y; Nakatsuka E; Kobayashi M; Miyamoto M; Ishida K; Matsumoto Y; Kodama M; Hashimoto K; Mabuchi S; Kimura T
    BMC Cancer; 2018 Nov; 18(1):1065. PubMed ID: 30396333
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasma microRNAs as potential new biomarkers for early detection of early gastric cancer.
    Zhu XL; Ren LF; Wang HP; Bai ZT; Zhang L; Meng WB; Zhu KX; Ding FH; Miao L; Yan J; Wang YP; Liu YQ; Zhou WC; Li X
    World J Gastroenterol; 2019 Apr; 25(13):1580-1591. PubMed ID: 30983818
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker.
    Erbes T; Hirschfeld M; Rücker G; Jaeger M; Boas J; Iborra S; Mayer S; Gitsch G; Stickeler E
    BMC Cancer; 2015 Mar; 15():193. PubMed ID: 25886191
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
    Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
    Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Prospective Analysis of Circulating Plasma Metabolites Associated with Ovarian Cancer Risk.
    Zeleznik OA; Eliassen AH; Kraft P; Poole EM; Rosner BA; Jeanfavre S; Deik AA; Bullock K; Hitchcock DS; Avila-Pacheco J; Clish CB; Tworoger SS
    Cancer Res; 2020 Mar; 80(6):1357-1367. PubMed ID: 31969373
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Integrated microRNA and mRNA signatures in peripheral blood lymphocytes of familial epithelial ovarian cancer.
    Dou YD; Huang T; Wang Q; Shu X; Zhao SG; Li L; Liu T; Lu G; Chan WY; Liu HB
    Biochem Biophys Res Commun; 2018 Jan; 496(1):191-198. PubMed ID: 29307835
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass.
    Oliveira DNP; Carlsen AL; Heegaard NHH; Prahm KP; Christensen IJ; Høgdall CK; Høgdall EV
    PLoS One; 2019; 14(11):e0225249. PubMed ID: 31738788
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression of microRNAs in the urine of patients with bladder cancer.
    Wang G; Chan ES; Kwan BC; Li PK; Yip SK; Szeto CC; Ng CF
    Clin Genitourin Cancer; 2012 Jun; 10(2):106-13. PubMed ID: 22386240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.